Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Rating of “Moderate Buy” from Brokerages

Palisade Bio, Inc. (NASDAQ:PALI) has received an average recommendation of “Moderate Buy” from the six analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $16.00.

A number of brokerages have recently weighed in on PALI. Citigroup reaffirmed a “buy” rating on shares of Palisade Bio in a research note on Tuesday, November 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Palisade Bio in a research report on Thursday. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd. Clear Str upgraded Palisade Bio to a “strong-buy” rating in a research note on Monday, December 29th. Finally, B. Riley initiated coverage on Palisade Bio in a research note on Friday, January 9th. They issued a “buy” rating and a $7.00 price target on the stock.

Palisade Bio Stock Up 3.2%

Shares of PALI stock opened at $1.91 on Monday. The firm has a market capitalization of $284.59 million, a price-to-earnings ratio of -0.90 and a beta of 1.43. The stock has a fifty day moving average of $2.01 and a 200 day moving average of $1.46. Palisade Bio has a 52 week low of $0.53 and a 52 week high of $2.64.

Palisade Bio (NASDAQ:PALI) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.06). Equities research analysts anticipate that Palisade Bio will post -12.43 earnings per share for the current year.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.